Amedisys (AMED)
(Delayed Data from NSDQ)
$96.71 USD
-0.09 (-0.09%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $96.71 0.00 (0.00%) 5:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.71 USD
-0.09 (-0.09%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $96.71 0.00 (0.00%) 5:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
Zacks News
Amedisys (AMED) New Buyouts Aid Growth, Margin Pressure Stays
by Zacks Equity Research
Amedisys' (AMED) newly-formed high-acuity care segment experiences solid momentum in the first quarter.
Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Impressive performance by the Home Health and Hospice segments drove Amedisys' (AMED) revenues in the first quarter.
Amedisys (AMED) Q1 Earnings Top Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 10.81% and 2.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Amedisys (AMED) Stock For Now
by Zacks Equity Research
Investors are optimistic about Amedisys' (AMED) strong segmental performance and strategic buyouts.
Why Is Amedisys (AMED) Up 13.2% Since Last Earnings Report?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for March 9th
by Zacks Equity Research
AGESY, AMED, and APAM have been added to the Zacks Rank #5 (Strong Sell) List on March 9, 2022.
New Strong Sell Stocks for March 4th
by Zacks Equity Research
AMED, CACC, and EXPO have been added to the Zacks Rank #5 (Strong Sell) List on March 4, 2022
Amedisys (AMED) Q4 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Robust performances by the Home Health and Hospice segments drove Amedisys' (AMED) fourth-quarter top line.
Amedisys (AMED) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 0.86% and 0.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics (DGX) Lags Q4 Earnings Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of -0.60% and 0.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for December 29th
by Zacks Equity Research
B, FPI, CGNX, AMED, and FSUGY have been added to the Zacks Rank #5 (Strong Sell) List on December 29, 2021.
New Strong Sell Stocks for December 27th
by Zacks Equity Research
TXRH, VIOT, WBK, AMED and CGNX have been added to the Zacks Rank #5 (Strong Sell) List on December 27, 2021
Why Is Amedisys (AMED) Down 22.9% Since Last Earnings Report?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for December 2nd
by Zacks Equity Research
AMED, LGIH, SWK, TCMD, and HEINY have been added to the Zacks Rank #5 (Strong Sell) List on December 2, 2021.
New Strong Sell Stocks for November 26th
by Zacks Equity Research
COLD, ENR, KSU, FSTR, and AMED have been added to the Zacks Rank #5 (Strong Sell) List on November 26, 2021.
New Strong Sell Stocks for November 19th
by Zacks Equity Research
AMED, CSII, DVA, GFF, and LTRX have been added to the Zacks Rank #5 (Strong Sell) List on November 19, 2021.
New Strong Sell Stocks for November 5th
by Zacks Equity Research
BLMN, AMED, HL, LGIH, and PLMR have been added to the Zacks Rank #5 (Strong Sell) List on November 5, 2021.
Amedisys (AMED) Tops Q3 Earnings Estimates, Slashes '21 View
by Zacks Equity Research
Amedisys (AMED) reports better-than-expected earnings for the third quarter on strong growth in the Home Health segment.
Amedisys (AMED) Beats Q3 Earnings Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 12.50% and -2.65%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Amedisys (AMED) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LHC Group (LHCG) Finalizes Home Health & Hospice Buyout Deals
by Zacks Equity Research
LHC Group (LHCG) to expand in Virginia Beach with the completion of the previously announced acquisition agreements with two providers, one in home health and the other in hospice.
EHC or AMED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EHC vs. AMED: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to benefit from strategic deals and broad array of services.
EHC or AMED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EHC vs. AMED: Which Stock Is the Better Value Option?
Amedisys (AMED) Down 6.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.